Post-translational modification of proteins by poly(ADP-ribosyl) ation regulates many cellular pathways that are critical for genome stability, including DNA repair, chromatin structure, mitosis and apoptosis 1 . Poly(ADP-ribose) (PAR) is composed of repeating ADPribose units linked via a unique glycosidic ribose-ribose bond, and is synthesized from NAD by PAR polymerases 1, 2 . PAR glycohydrolase (PARG) is the only protein capable of specific hydrolysis of the riboseribose bonds present in PAR chains; its deficiency leads to cell death 3, 4 .
Here we show that filamentous fungi and a number of bacteria possess a divergent form of PARG that has all the main characteristics of the human PARG enzyme. We present the first PARG crystal structure (derived from the bacterium Thermomonospora curvata), which reveals that the PARG catalytic domain is a distant member of the ubiquitous ADP-ribose-binding macrodomain family 5, 6 . High-resolution structures of T. curvata PARG in complexes with ADP-ribose and the PARG inhibitor ADP-HPD, complemented by biochemical studies, allow us to propose a model for PAR binding and catalysis by PARG. The insights into the PARG structure and catalytic mechanism should greatly improve our understanding of how PARG activity controls reversible protein poly(ADP-ribosyl) ation and potentially of how the defects in this regulation are linked to human disease.
Whereas the mechanism and functional aspects of PAR synthesis have been extensively characterized, the present understanding of the PAR-degradation pathways catalysed by PARG is comparatively poor. Until now, the catalytic fold and the mechanism of PARG-mediated hydrolysis have remained unknown. Our homology searches revealed that the majority of fungal genomes lack close mammalian/canonical PARG homologues, but instead possess a divergent PARG-like protein, annotated as DUF2263. DUF2263 protein sequences contain the PARG signature (GGG-X 6-8 -QEE) 7 , which includes the previously identified key residues: two consecutive glutamates 7 (Fig. 1a , black asterisk) and a glycine 8 (Fig. 1a , grey asterisk). In addition, a tyrosine residue ( Fig. 1a , black cross) implicated in binding to the PARG inhibitor ADP-HPD 9 is also present in DUF2263. The DUF2263 orthologue is found also in other eukaryotes lacking canonical PARGs such as the rotifer Adineta vaga (Fig. 1b) , where it is fused to several copies of the PAR-binding zinc finger 10 . As both filamentous fungi and A. vaga have functional PARP orthologues and an active PAR metabolism 11, 12 , we postulated that DUF2263 was likely to be a functional PARG in these organisms. Surprisingly, although bacteria are historically thought to be devoid of PAR metabolism, certain bacterial species possess both PARP (closely related to PARP1; ref 13) and DUF2263 genes, whereas some only contain the DUF2263 homologue ( Fig. 1a, b ). To analyse the biochemical activities of the corresponding bacterial PARP and PARG proteins, we purified His 6 -tagged Herpetosiphon aurantiacus PARP and DUF2263. H. aurantiacus PARP was able to synthesize PAR from NAD, as revealed by antibodies recognizing PAR ( Fig. 1c) and by the analysis of PAR ladders using sequencing gels (Supplementary Fig. 1 ). Analogous to the human PARP1 enzyme, H. aurantiacus PARP was sensitive to the PARP inhibitor KU-0058948 and required DNA for its activation (Fig. 1c ). Notably, poly(ADP-ribosyl)ation produced by H. aurantiacus PARP is efficiently hydrolysed by the H. aurantiacus DUF2263 protein, demonstrating that DUF2263 is a functional PARG ( Fig. 1c ) and suggesting the presence of functional PAR metabolism in bacteria.
We extended our analyses to other bacterial and fungal PARGs (Fig. 1a, b and Supplementary Fig. 2 ) using established PAR substrates formed by the activity of the well-characterized human PARP1 enzyme. Canonical human and Entamoeba dispar PARGs served as controls. The in vitro activity of the purified PARG enzymes was evaluated in five ways: (1) an assay that measures the loss of PAR from PARP1-modified histones; (2) a western-blot analysis of the hydrolysis of PAR from the auto-modified human PARP1 using anti-PAR antibodies; (3) an SDSpolyacrylamide gel electrophoresis (SDS-PAGE) analysis of the [ 32 P]-PAR auto-modified human PARP1; (4) an analysis of the release of ADP-ribose from PAR either by thin-layer chromatography (TLC); or (5) by liquid chromatography-mass spectrometry (LC/MS) ( Fig. 2a-d and Supplementary Fig. 4 ). The quantification of PAR hydrolysis by the PARG assay shows that bacterial and fungal PARGs are highly active in hydrolysing PAR in vitro; their catalytic potency is comparable to the E. dispar and human PARG enzymes ( Fig. 2a ). Moreover, the mode of action of these proteins and mutant versions on poly(ADP-ribosyl)ated PARP1 shows the same pattern observed for the canonical PARGs. First, they are all inactivated by the mutation of a key glutamate residue ( Fig. 2b, d ) and by treatment with the PARG inhibitor ADP-HPD ( Fig. 2c ). Second, they are all active on ribose-ribose bonds between the two ADP-ribose units, but they are not efficient on mono(ADPribosyl)ated protein substrates with the ADP-ribose unit linked directly to the PARP1 (Fig. 2c ) or the PARP10 protein ( Supplementary Fig. 3 ). Last, TLC and LC/MS analyses confirmed that the main product of DUF2263-type PARGs is ADP-ribose ( Fig. 2d and Supplementary  Fig. 4 ). Collectively, these results demonstrate that bacterial and fungal PARG proteins possess genuine PARG activity in vitro.
To test whether bacterial and fungal PARG proteins can act as PARGs in vivo, we used the Saccharomyces cerevisiae system expressing human PARP1 (ref. 14) . Yeast cells, naturally deficient in PAR metabolism, can readily express human PARP1, resulting in poly(ADPribosyl)ation of various protein substrates 14 ( Fig. 2e ). When divergent PARG proteins were co-expressed with human PARP1, we observed that the poly(ADP-ribosyl)ation levels in yeast extracts diminished, indicating an efficient hydrolysis of PAR in vivo ( Fig. 2e and Supplementary Fig. 5 ).
Although the first PARG gene was cloned in 1997 (ref. 15) , until now there has been no structural data available for a PARG enzyme. To gain an insight into the PARG structure and mechanism, we solved the T. curvata PARG ligand-free crystal structure to 1.5 Å in addition to ADP-ribose and ADP-HPD inhibitor-bound structures (Supplementary Table 1 ). Comparison with available structures reveals that T. curvata PARG consists of an ADP-ribose-binding macrodomain fold with an amino-terminal extension (residues 3-67; Fig. 3c 16 . The diphosphatebinding loop that flanks one side of the ADP-ribose-binding cavity is highly conserved between PARG and other macrodomain structures (in magenta, Fig. 3a, c) . In contrast, the opposite side of the PARG ADP-ribose-binding cavity is lined by a stretch of amino acids corresponding to the PARG-specific GGG-X 628 -QEE signature sequence 7 (in yellow, Fig. 3a -c). The structural alignment reveals this PARGspecific loop is inserted into the macrodomain fold to accommodate the Glu 115 side chain that projects into the PARG active site ( Fig. 3c,  d ). Owing to the PARG-specific loop, it seems that only PARGs but not other macrodomain proteins can hydrolyse PAR ( Supplementary  Fig. 6 ).
The ligand-PARG complex structures reveal that ADP-a-ribose occupies a position similar to that observed in other ADP-ribosemacrodomain complex structures 5 ( Fig. 3d and Supplementary Fig. 7) . A minor rearrangement can be observed for Val 226-Phe 227 upon ADP-ribose binding. The Phe 227 side chain is in close contact with the ribose99 moiety of ADP-ribose, ensuring a close distance between the ribose99 O4 and one of the phosphate groups within the constraints of the active site. The ribose99 moiety also forms hydrogen bonds with Glu 114 (via the 29-OH group) and Glu 115 (via the 19-OH group) ( Fig. 3d ). With the exception of water-mediated polar contacts, few direct contacts can be observed with the adenosine moiety. In contrast to the ribose99 moiety, the adenosine ribose9 moiety is markedly less accessible. The presence of any substituents on the ribose9 29-OH group (such as another ADP-ribose) would require a major reorientation of the PARG carboxy-terminal a-helix (see Fig. 4a ) with concomitant * ** 
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exposure of the hydrophobic core of the macrodomain. This suggests that bacterial PARG binds the PAR terminus and acts as an exoglycohydrolase. The steric restraints imposed by the PARG active site form a basis for the modelling of an a(199R29) O-glycosidic linkage with an additional ADP-ribose group to provide further insight into PAR binding (Fig. 4a, b ). Our models suggest that the (n 2 1) adenine moiety is partially enclosed by Ala 110, Ala 112 and Val 226 while the (n 2 1) ribose9 is in close contact with Ser 98 and Gly 104 (Fig. 4b ). However, molecular dynamics simulations suggest that the enzyme lacks any obvious binding sites for the (n 2 1) phosphate and ribose99 moieties, as exemplified by the considerable conformational freedom of the latter with respect to the terminal ADP-ribose and the associated (n 2 1) ribose9. This suggests that bacterial PARG does not specifically bind additional PAR elements.
The T. curvata PARG complex with ADP-ribose ( Fig. 3d ) and the corresponding PAR-PARG model (Fig. 4b) allow us to propose a mechanism for PARG catalysis (Fig. 4c ). Binding of the PAR terminus positions the key ribose-ribose O-glycosidic linkage in direct hydrogenbonding contact with Glu 115, while constraining the conformation of the terminal ribose99. Formation of a putative oxocarbenium intermediate is supported by the protonation of the (n 2 1) PAR ribose9 29-OH leaving group via Glu 115, and by the stabilization of the positively charged oxocarbenium through close proximity with the terminal diphosphate group. A water molecule is ideally positioned to attack the oxocarbenium intermediate, activated through concomitant deprotonation by Glu 115. This leads to the release of ADP-b-ribose99 and (n 2 1) PAR.
This mechanism is supported by mutagenesis and binding studies. Although mutations of both Glu 114 and Glu 115 render the enzyme 
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inactive without disruption to the overall PARG fold ( Fig. 4d and Supplementary Fig. 8 ), the isothermal titration calorimetry (ITC) ADP-ribose binding studies reveal that mutation of Glu 115 into an alanine does not affect binding, whereas the Glu114Ala mutation leads to an approximately tenfold decrease in binding affinity (Supplementary Fig. 9 ). This supports the notion that the role of Glu 114 is confined to substrate binding/orientation as opposed to the acid-base catalysis proposed for Glu 115. The mutation of Phe 227 implicated in positioning the terminal ribose99 also renders the enzyme inactive ( Fig. 4d ). Mutations of Ser 98 and Val 226, implicated by our model in binding the (n 2 1) ADP-ribose, greatly diminish T. curvata PARG activity (Fig. 4d ). Importantly, mutations of the corresponding catalytic residues in human PARG have a similar effect on the enzymatic activity, which suggests a universal catalytic mechanism for bacterial and mammalian PARGs (Fig. 4d) . These data provide the first insight into PARG structure and catalytic mechanism, and improve our understanding of the biochemical strategies regulating reversible poly(ADP-ribosyl)ation. Our results indicate the existence of bacterial PAR metabolism and show that PARG is a member of the widespread macrodomain protein family 5, 6 , which is known to be implicated in genome stability and regulated by poly(ADP-ribosyl)ation [17] [18] [19] . Our data confirm that PARGs are evolutionary unrelated to ARH3 proteins, another class of enzymes with the ability to cleave PAR 20,21 (Supplementary Information). We believe that our findings will provide the groundwork for future studies that 
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might ultimately lead to the development of small, cell-permeable PARG inhibitors and the potential to manipulate the physiology of health and disease by interfering with PAR metabolism.
METHODS SUMMARY
Proteins with His 6 -tags were purified from E. coli. A colourimetric PARG Assay Kit (Trevigen) was used to measure the loss of biotinylated PAR from histones. Auto-modified poly(ADP-ribosyl)ated human and bacterial PARP substrates were made by incubation with NAD 10 . In vivo activity of PARGs was tested in a yeast system with inducible expression of human PARP1. The T. curvata PARG structure was solved by means of single-wavelength anomalous diffraction on Ptsoaked crystals. Ligand-enzyme complexes were obtained by the soaking of PARG crystals. The PAR-PARG model was created using molecular dynamics simulations of the ADP-a-ribose dimer in complex with PARG.
(Waters Corp.). Binary gradients at a flow rate of 0.4 ml min 21 were applied for the elution. The eluent A was water containing 5 mmol l 21 of pentylamine, while the pH value was adjusted to 6.5 using acetic acid. A fast elution gradient was applied, which allowed an efficient separation of NAD1 and ADP-ribose within 5 min. The gradient started at 2% B and then the percentage of B linearly increased to 25% in 5 min. The mass spectrometry was performed on a QTOF Premier instrument (Waters Micromass) using an orthogonal Z-spray-electrospray interface. The drying gas and the nebulizing gas was nitrogen. The desolvation gas flow was set to 700 l h 21 at a temperature of 300 uC. The cone gas flow was adjusted to 25 l h 21 , and the source temperature to 120 uC. The capillary and cone voltages were 3,200 V and 30 V respectively. The instrument was operated in V mode with TOFMS data being collected between m/z 100-1,000, applying a collision energy of 4 eV. All spectra were recorded using the extended dynamic range (DRE) option in order to correct for possible peak saturations, the data were collected in the centroid mode with a scan time of 0.08 s and interscan time of 0.02 s. In order to ensure maximum accuracy and reproducibility of the system, all acquisitions were carried out using an independent reference spray via the lock spray interface. Leucine enkephalin was applied as a lock mass in negative ionization mode (m/z 554.2615).
The chromatograms, recorded in the total ion current (TIC) mode, were systematically examined by manually generating mass spectra of each visible individual peak using the background-subtraction option and searching for target components expected to occur in the mixture, in particular ADP-ribose and NAD1, using extracted ion chromatograms. The target analyses were based on the accurate mass feature of the instrument, applying a mass window of 50 mDa.
Elemental composition of the selected ions was calculated using the MassLynx software incorporated in the instrument. The main criterion for selecting the elements to be included in search parameters for the calculation of the molecular formula was the elemental composition of the presumed parent compounds. According to the instrument specifications, the acceptable deviation from the theoretical m/z values was set at 5 mDa.
